First Tracks Biotherapeutics Inc (TRAX)

$17.64 +0.61 (3.58%)
Market Cap 594.21M
Revenue (ttm) 0.00
Net Income (ttm) -163.71M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.00
Volume 415,300
Avg Vol N/A
Day's Range N/A - N/A
Shares Out 34.89M
Stochastic %K 78%
Beta N/A
Analysts Strong Sell
Price Target $38.12

Company Profile

First Tracks Biotherapeutics, Inc. operates a clinical-stage biotechnology company focused on delivering immunology therapeutics for autoimmune and inflammatory diseases in United States. Its products includes ANB033, a novel anti-CD122 antagonist that targets the shared beta subunit of the IL-15 and IL-2 receptors; Rosnilimab, a antibody engineered to selectively deplete pathogenic T cells in both the periphery and inflamed tissues; and ANB101, a BDCA2-modulating antibody designed to specifical...

Industry: Biotechnology
Sector: Healthcare
Phone: 858 362 6295
Address:
10770 Wateridge Circle, Suite 210, San Diego, United States
Latest News on TRAX
First Tracks Biotherapeutics initiated with an Overweight at Wells Fargo

2026-06-08T09:00:08.000Z - 5 days ago

First Tracks Biotherapeutics initiated with an Overweight at Wells Fargo

First Tracks Biotherapeutics Announces Participation in Upcoming Investor Conferences

May 21, 2026, 4:15 PM EDT - 22 days ago

First Tracks Biotherapeutics Announces Participation in Upcoming Investor Conferences

First Tracks Biotherapeutics Announces First Quarter 2026 Financial Results and Provides Business Update

May 14, 2026, 4:15 PM EDT - 4 weeks ago

First Tracks Biotherapeutics Announces First Quarter 2026 Financial Results and Provides Business Update

First Tracks Biotherapeutics Earnings release: Q1 2026

May 14, 2026, 7:00 AM EDT - 4 weeks ago

First Tracks Biotherapeutics Earnings release: Q1 2026

First Tracks Biotherapeutics Quarterly report: Q1 2026

May 14, 2026, 7:00 AM EDT - 4 weeks ago

First Tracks Biotherapeutics Quarterly report: Q1 2026

First Tracks Biotherapeutics Slides: Corporate presentation

May 14, 2026, 7:00 AM EDT - 4 weeks ago

First Tracks Biotherapeutics Slides: Corporate presentation

First Tracks Biotherapeutics files to sell 10.5M shares of common for holders

2026-05-08T22:52:09.000Z - 5 weeks ago

First Tracks Biotherapeutics files to sell 10.5M shares of common for holders

First Tracks Biotherapeutics Registration statement: Registration filing

May 8, 2026, 8:00 AM EDT - 5 weeks ago

First Tracks Biotherapeutics Registration statement: Registration filing

First Tracks Biotherapeutics initiated with an Overweight at Piper Sandler

2026-05-04T08:40:30.000Z - 5 weeks ago

First Tracks Biotherapeutics initiated with an Overweight at Piper Sandler

First Tracks Biotherapeutics initiated with a Buy at H.C. Wainwright

2026-04-28T10:10:15.000Z - 6 weeks ago

First Tracks Biotherapeutics initiated with a Buy at H.C. Wainwright

First Tracks Biotherapeutics initiated with an Outperform at Leerink

2026-04-24T11:36:50.000Z - 7 weeks ago

First Tracks Biotherapeutics initiated with an Outperform at Leerink

ANAB

First Tracks Biotherapeutics initiated with an Overweight at Barclays

2026-04-23T12:11:58.000Z - 7 weeks ago

First Tracks Biotherapeutics initiated with an Overweight at Barclays

First Tracks Biotherapeutics initiated with an Overweight at JPMorgan

2026-04-23T12:11:27.000Z - 7 weeks ago

First Tracks Biotherapeutics initiated with an Overweight at JPMorgan

First Tracks Biotherapeutics Debuts on Nasdaq to Advance Therapies for Autoimmune Diseases

Apr 20, 2026, 9:15 AM EDT - 7 weeks ago

First Tracks Biotherapeutics Debuts on Nasdaq to Advance Therapies for Autoimmune Diseases